"Medical headlines" drug K was approved as a new indication, and Shenzhou, a stone medicine, plans to break up
-
Last Update: 2020-01-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
(2020 / 01 / 09) blueprint announced the key clinical trial results of RET precision therapy for lung cancer; keytruda was approved as the first PD-1 therapy for NMIBC with new indications; overview of the pattern of CD20 monoclonal antibody to be broken up in Shenzhou, a Chinese medicine; progress report on the consistency evaluation of generic drugs in 2019 K medicine is powerful Break up or be a good friend The speed of consistency evaluation is faster The "production capacity" of the drug audit center can't keep up It's good to have risks.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
